ING1: A Drug Target and Biomarker for the Treatment of Lung Cancer

Target Name: ING1

NCBI ID: G3621

ING1

ING1: A Drug Target and Biomarker for the Treatment of Lung Cancer

Pulmonary cancer is one of the leading causes of cancer-related deaths worldwide, with an estimated 200,000 new cases and 150,000 cancer deaths in the United States alone in 2020. The development of new treatments for this disease remains a major focus of research, and the identification of potential drug targets and biomarkers could lead to new and more effective therapies. One promising candidate for drug targeting and biomarker development is ING1, an inhibitor of growth protein 1.

ING1 and Cancer

ING1 is a protein that is expressed in various tissues and cell types, including epithelial, muscle, and neural cells. It is a key regulator of cell growth and has been implicated in the development and progression of many types of cancer. In particular, ING1 has been shown to be overexpressed or mutated in many types of cancer, including lung cancer.

Studies have shown that ING1 is often overexpressed or mutated in lung cancer, and that this increase in expression or mutation can lead to the formation of cancer stem cells. These cancer stem cells can then promote the development and progression of new cancerous tumors. Additionally, ING1 has been shown to promote the growth and survival of many types of cancer cells, which could make it an attractive target for new therapies.

ING1 as a Drug Target

The potential of ING1 as a drug target is due to its unique mechanism of action and its potential to disrupt the signaling pathways that drive cancer cell growth and survival. ING1 works by inhibiting the formation of actin filaments, which are important for the maintenance of cell structure and cytoskeleton. This inhibition leads to the relaxation of cell cytoskeleton, allowing cells to change their shape and move freely, which can be a critical step in the development of cancer.

ING1 has been shown to be a potent inhibitor of actin filament formation in a variety of cancer cells, including lung cancer cells. Studies have shown that ING1 can significantly reduce the growth and survival of lung cancer cells, and that this effect is dose-dependent. Additionally, ING1 has been shown to inhibit the migration and invasion of cancer cells, which are critical steps in the development of new tumors.

ING1 as a Biomarker

The potential use of ING1 as a biomarker for the diagnosis and prognosis of cancer is also an exciting area of research. As ING1 has been shown to be overexpressed or mutated in many types of cancer, it may be a useful indicator of the severity and stage of these cancers. Additionally, ING1 has been shown to be a potential predictor of cancer outcomes, with higher ING1 expression or mutation levels predicting poor prognosis in many types of cancer.

ING1 has also been shown to be a potential biomarker for the treatment of cancer. Studies have shown that inhibiting ING1 can significantly enhance the effectiveness of many chemotherapy drugs, including those used to treat lung cancer. Additionally, ING1 has been shown to be downregulated in the tumors of patients who have been treated with anti-cancer drugs, which could be a potential indicator of the effectiveness of these treatments.

Conclusion

ING1 is a promising candidate for drug targeting and biomarker development for the treatment of lung cancer. Its unique mechanism of action and its potential to disrupt the signaling pathways that drive cancer cell growth and survival make it an attractive target for new therapies. Further research is needed to fully understand the role of ING1 in the development and treatment of cancer.

Protein Name: Inhibitor Of Growth Family Member 1

Functions: Cooperates with p53/TP53 in the negative regulatory pathway of cell growth by modulating p53-dependent transcriptional activation. Implicated as a tumor suppressor gene

The "ING1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ING1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets